Compare Merck & Co., Inc. (MRK) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Motorola Solutions Inc — how do they compare? Merck & Co., Inc. trades at $133.51 (market cap $321.77B), while Motorola Solutions Inc trades at $467.7 (market cap $77.26B). The key difference: Merck & Co., Inc. is far larger — about 4.2× Motorola Solutions Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| MRK | MSI | |
|---|---|---|
Market Cap | $321.77B | $77.26B |
Sector | Health | Technology |
52-Week High | $131.84 | $490.30 |
52-Week Low | $77.60 | $363.83 |
Enterprise Value | $368.53B | $86.17B |
Dividend Yield | 2.61% | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Motorola Solutions (MSI) trades at $466.53, up 0.98% today, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.41 exceeding expectations, and the company raised its full-year guidance. Revenue growth is robust, supported by a record backlog of $15.6 billion, while profitability remains high with a net income margin of 17.44%.
The outlook is positive given strong demand in public safety and software services, though valuation multiples are elevated. Key risks include execution challenges and macroeconomic sensitivity. Analyst consensus is bullish with a $533.80 price target, implying significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
